CD274 and kidney cancer: This finding suggested that kidney cancer cell lines with wild-type TUBA1C are more susceptible to anti-PD-L1 therapy, and, conversely, that TUBA1C mutations may confer enhanced resistance to anti-PD-L1 therapy.